open access

https://hdl.handle.net/2115/80387

Sodium–glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

英語

glucose variability

2021-02

John Wiley & Sons

Journal of Diabetes Investigation

12(2)

176-183

Introduction: SGLT2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes (T1DM). Materials and Methods: Patients with T1DM who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day‐to‐day glucose variability, as the primary endpoint, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring (CGM). Results: Fifty‐one patients (37 women; mean age 52.7 years) were included. HbA1c and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 ± 26.6 to 38.7 ± 24.3 units/day). CGM data were obtained from 30 patients. P25/P75 decreased by 17.6 ± 20.7% during SGLT2i treatment (P <0.001). The percentage of time per day within the target glucose range of 70?180 mg/dL significantly increased (from 42.2% to 55.5%, P <0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis. Conclusions: SGLT2i improved day‐to‐day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with T1DM, and reduced HbA1c, body mass, and the required insulin dose.

学術雑誌論文

Version of Record

Creative Commons Attribution-NonCommercial 4.0 International

2040-1116

2040-1124